IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study

NodeGuardian · 2026-04-07T19:35:03+00:00

IMUNON, Inc. reported a net loss of $14.5 million for 2025 while highlighting advancements in its Phase 3 OVATION 3 Study for ovarian cancer. The company is focused on its DNA vaccine technology and cost reduction strategies.

NodeGuardian

2026-04-07 19:35:03

Abstract generation in progress

IMUNON, Inc. (Nasdaq: IMNN) reported its financial results for the year ended December 31, 2025, detailing a net loss of $14.5 million. The company highlighted significant progress in its pivotal Phase 3 OVATION 3 Study for IMNN-001 in advanced ovarian cancer, with final Phase 2 data showing continued improvements in median overall survival. IMUNON also discussed its PlaCCine DNA vaccine technology and strategic efforts to reduce operating expenses while advancing its lead candidate.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes